Literature DB >> 15901935

Evaluating response to antineoplastic drug combinations in tissue culture models.

C Patrick Reynolds1, Barry J Maurer.   

Abstract

The mainstay of clinical antineoplastic chemotherapy is multiagent combinations, most of which were developed empirically. Because of the desire to speed research and decrease costs, there is increasing interest in moving new drugs into clinical trials in potentially active combinations based on preclinical testing data. Different mathematical models have been proposed for evaluating drug interactions, which can be classified as synergistic (combinations demonstrating greater than the additive activity expected from each agent alone), additive, or antagonistic (drugs showing less activity in combination than expected from the sum of each agent alone). Here, we briefly review some of the principles for testing cytotoxic drug interactions. We focus this review on application of the Combination Index method (as developed by Chou and colleagues) in the evaluation of drug interactions in cell culture assays.

Mesh:

Year:  2005        PMID: 15901935     DOI: 10.1385/1-59259-869-2:173

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  35 in total

Review 1.  Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors:  Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

3.  GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.

Authors:  Shaolin Ma; Sunila Pradeep; Alejandro Villar-Prados; Yunfei Wen; Emine Bayraktar; Lingegowda S Mangala; Mark Seungwook Kim; Sherry Y Wu; Wei Hu; Cristian Rodriguez-Aguayo; Carola Leuschner; Xiaoyan Liang; Prahlad T Ram; Katharina Schlacher; Robert L Coleman; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2019-03-29       Impact factor: 6.261

4.  RNAi screening of the kinome with cytarabine in leukemias.

Authors:  Raoul Tibes; James M Bogenberger; Leena Chaudhuri; R Tanner Hagelstrom; Donald Chow; Megan E Buechel; Irma M Gonzales; Tim Demuth; James Slack; Ruben A Mesa; Esteban Braggio; Hongwei H Yin; Shilpi Arora; David O Azorsa
Journal:  Blood       Date:  2012-01-20       Impact factor: 22.113

5.  In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor.

Authors:  Senna Sakai; Hiroto Izumi; Yukiko Yoshiura; Yoshifumi Nakayama; Takahiro Yamaguchi; Yoshikazu Harada; Chiho Koi; Hiroyuki Kurata; Yasuo Morimoto
Journal:  Oncol Lett       Date:  2016-09-20       Impact factor: 2.967

6.  Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.

Authors:  Xianbiao Xie; Markus P H Ghadimi; Eric D Young; Roman Belousov; Quan-Sheng Zhu; Juehui Liu; Gonzalo Lopez; Chiara Colombo; Tingsheng Peng; David Reynoso; Jason L Hornick; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-08-05       Impact factor: 12.531

7.  Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.

Authors:  David Reynoso; Laura K Nolden; Dan Yang; Sarah N Dumont; Anthony P Conley; Amaury G P Dumont; Kim Zhou; Anette Duensing; Jonathan C Trent
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

8.  The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Authors:  Alexandra Canonici; Zulfiqar Qadir; Neil T Conlon; Denis M Collins; Neil A O'Brien; Naomi Walsh; Alex J Eustace; Norma O'Donovan; John Crown
Journal:  Invest New Drugs       Date:  2018-02-02       Impact factor: 3.850

9.  Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.

Authors:  Zhengxing Qu; David M Goldenberg; Thomas M Cardillo; Victoria Shi; Hans J Hansen; Chien-Hsing Chang
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

10.  In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors.

Authors:  Natalia Skobeleva; Sanjay Menon; Lutz Weber; Erica A Golemis; Vladimir Khazak
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.